Both CD4+FoxP3+ and CD4+FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro

Immunology

Volumn 133, Issue 3, 2011, Pages 296-306

  Lindqvist, Camilla A ^a   Christiansson, Lisa H ^a   Thörn, Ingrid ^a   Mangsbo, Sara ^a,b   Paul Wetterberg, Gabriella ^a   Sundström, Christer ^a   Tötterman, Thomas H ^a   Simonsson, Bengt ^c   Enblad, Gunilla ^a   Frisk, Per ^c   Olsson Strömberg, Ulla ^c   Loskog, Angelica S I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B cell lymphoma; CD107a; Chronic lymphocytic leukaemia; Fas ligand; FoxP3; Granzyme; Precursor B cell acute lymphoblastic leukaemia

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; GRANZYME; INTERLEUKIN 7 RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; T-LYMPHOCYTES, REGULATORY;

EID: 79957872910     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03439.x     Document Type: Article

References (58)

1. + cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010; 29:371-402.
2. + regulatory T cells. Nat Immunol 2003; 4:330-6.
3. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, NY) 2003; 299:1057-61.
4. + T regulatory cells. Nat Immunol 2003; 4:337-42.
5. + regulatory T cells. Int Immunol 2004; 16:1643-56.
6. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010; 107:57-117.
7. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev 2008; 8:523-32.
8. + T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003; 171:4604-12.
9. + responder cells by Fas-mediated apoptosis. J Immunol 2009; 182:1469-80.
10. + T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010; 32:266-78.
11. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-46.
12. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21:589-601.
13. Mahnke K, Bedke T, Enk AH. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007; 250:1-13.
14. + T cells selectively kill B lymphocytes. Blood 2006; 107:3925-32.
15. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104:2840-8.
16. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5:251-62.
17. Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010; 131:371-6.
18. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009; 254:149-54.
19. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
20. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30:180-92.
21. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005; 102:5138-43.
22. Zhou Z, Song X, Berezov A, Li B, Greene MI. Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target. Int Immunopharmacol 2009; 9:518-20.
23. Zhou Z, Song X, Li B, Greene MI. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008; 42:19-28.
24. Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A, Glennie MJ, Porakishvili N. Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype. Br J Haematol 2010; 148:274-84.
25. + T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004; 89:435-43.
26. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42.
27. Liu YJ, de Bouteiller O, Fugier-Vivier I. Mechanisms of selection and differentiation in germinal centers. Curr Opin Immunol 1997; 9:256-62.
28. Choe J, Kim HS, Zhang X, Armitage RJ, Choi YS. Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J Immunol 1996; 157:1006-16.
29. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
30. + Tregs in lymphomas and tumors are complex. Front Biosci 2008; 13:3986-4001.
31. Alvaro T, Lejeune M, Escriva P et al. Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol 2009; 70:103-13.
32. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11:1467-73.
33. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957-64.
34. Lee NR, Song EK, Jang KY et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008; 49:247-56.
35. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200.
36. Wahlin BE, Aggarwal M, Montes-Moreno S et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 - positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16:637-50.
37. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128:958-65.
38. Koreishi AF, Saenz AJ, Persky DO, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J. The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2010; 18:206-11.
39. Rosen A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis. Semin Cancer Biol 2010; 20:400-9.
40. Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990; 76:562-9.
41. Sthoeger ZM, Wakai M, Tse DB et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989; 169:255-68.
42. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692-701.
43. Ekstrom Smedby K, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029-38.
44. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90:766-75.
45. Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51-60.
46. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65:796-803.
47. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-54.
48. - effector T cells. Int Immunol 2008; 20:421-31.
49. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-90.
50. + T cells. Eur J Immunol 2007; 37:129-38.
51. - cells. Eur J Immunol 2008; 38:1381-90.
52. + T reg cells. J Exp Med 2006; 203:1701-11.
53. Iikuni N, Lourenco EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 2009; 183:1518-22.
54. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85.
55. + regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103:3428-30.
56. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105:735-41.
57. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-88.
58. Leonardo SM, Josephson JA, Hartog NL, Gauld SB. Altered B cell development and anergy in the absence of Foxp3. J Immunol 2010; 185:2147-56.